Hexagon Capital Partners’s Kyntra Bio KYNB Stock Holding History

Hexagon Capital Partners’s Portfolio KYNB Stock Details KYNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-1	Closed	-$59	–	1430
2023 Q2	$59	Buy	+1	New	+$414	﹤0.01%	1399

Other funds holding KYNB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Hexagon Capital Partners's KYNB Position: Q3 2023 in Review

Hexagon Capital Partners sold out of Kyntra Bio (KYNB) in Q3 2023, closing a stake of 1 share — an estimated $59 sold.

Hexagon Capital Partners first reported a position in KYNB in Q2 2023 and held it in 1 quarter. The position peaked at $59 in Q2 2023. 110 funds tracked by Wall St. Rank hold KYNB as of Q3 2023.

Hexagon Capital Partners reported no remaining Kyntra Bio position as of Q3 2023 after selling out during the quarter.
Hexagon Capital Partners sold 1 Kyntra Bio share in Q3 2023, an estimated $59.
Hexagon Capital Partners first reported a position in Kyntra Bio in Q2 2023 and held it in 1 quarter.
Hexagon Capital Partners's Kyntra Bio position peaked at $59 in Q2 2023.
110 funds tracked by Wall St. Rank held Kyntra Bio as of Q3 2023.

Based on Hexagon Capital Partners's 13F filing for Q3 2023, filed 23 Oct 2023.